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Objectives: To evaluate the PSA in a large population of Brazilian men undergone to 
check up, and correlate the PSA cutoffs with prostate size and urinary symptoms.
Materials and Methods: This is a cross sectional study performed with men between 
40 and 70 years undergone to check-up. All men were undergone to urological evalu-
ation, digital rectal examination, prostate-specific antigen, and ultrasonography The 
exclusion criteria were men who used testosterone in the last six months, or who were 
using 5 alpha-reductase inhibitors.
Results: A total of 5015 men with an average age of 49.0 years completed the study. 
Most men were white and asymptomatic. The PSA in the three different aging groups 
were 0.9 ± 0.7ng/dL for men between 40 and 50; 1.2 ± 0.5ng/dL for men between 50 
and 60; and 1.7 ± 1.5ng/dL for men greater than 60 years (p=0.001). A total of 192 men 
had PSA between 2.5 and 4ng/ml. From these men 130 were undergone to prostate 
biopsy. The predictive positive value of biopsy was 25% (32/130). In the same way, 100 
patients had PSA >4ng/mL. From these men, 80 were undergone to prostate biopsy. In 
this group, the predictive positive value of biopsy was 40% (32/100). The Gleason score 
was 6 in 19 men (60%), 7 in 10 men (31%) and 8 in 3 men (9%).
Conclusions: The PSA level of Brazilian men undergone to check up was low. There 
was a positive correlation with aging, IPSS and prostate size.
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INTRODUCTION
Prostate cancer is the second most com-
monly diagnosed type of cancer in the world, and 
the sixth leading cause of death in men worldwide. 
On a global level the incidence and prevalence of 
prostate cancer varies more than 25-fold worldwi-
de, with highest incidence in developed countries 
of North America, Europe and Australia, and lo-
wer incidence rates in underdeveloped countries. 
These differences may occur due to the increased 
levels of screening and testing for prostate cancer 
in these developed countries (1-3).
The primary goal of prostate cancer scre-
ening is to reduce deaths due to prostate cancer, 
thus increasing life span. An additional important 
outcome of this type of screening would be a re-
duction in the development of symptomatic me-
tastatic disease. Contemporary recommendations 
for prostate cancer screening incorporate the mea-
surement of serum prostate-specific antigen (PSA) 
levels associated with other methods of detection 
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such as digital rectal examination and/or ultrasono-
graphy (4, 5).
With regards to screening accuracy, studies 
have demonstrated that a PSA cutoff of 4.0µg/L can 
detect many cases of prostate cancer; however, some 
will be missed. Using a lower cutoff level detects 
more cases, but at the cost of falsely labeling more 
men as potentially having cancer. Whether, for ins-
tance, the PSA cutoff is decreased to 2.5µg/dL, more 
than double the number of men aged 40 to 69 years 
will be labeled as a false positive (6, 7). These false 
positive results are associated with negative psycho-
logical effects. In addition, men who have a false 
positive result are more likely to have additional 
testing, including one or more biopsies in the year 
following diagnosis, as compared with those who 
have a negative test result. Almost one third of the-
se biopsied patients experience pain, fever, bleeding, 
infection, transient urinary difficulties, and 1% even 
require hospitalization (8,9).
Theoretically, the early detection of prostate 
cancer in younger asymptomatic men could signifi-
cantly reduce the mortality rates; however, in most 
cases those tumors will not progress or will progress 
so slowly that they would have remained asymp-
tomatic during the lifetime of the patient. The term 
overdiagnosis is used to describe this situation. Lo-
wer PSA cutoffs and screening tests performed in 
younger men increase the probability of overdiagno-
sis (10). There is a high propensity for physicians to 
treat most cases of screen-detected cancer, given our 
current inability to distinguish indolent from aggres-
sive tumors. Thus, many patients are being subjected 
to the harmful effects of prostate cancer treatment 
that will never become symptomatic (11,12).
The primary objective of this study was to 
evaluate the PSA levels in a large population of 
young Brazilian men submitted to a health check 
up program. The second objective was to correlate 
the different PSA cutoffs with aging, prostate size, 
and urinary symptoms.
MATERIAL AND METHODS
Data from the present study were collected 
from the check-up program performed between 
January and December 2011 at a private hospital 
in Sao Paulo, Brazil. This study was approved by 
local ethics committee and all patients signed out 
an informed consent.
During the examination, a multidisciplina-
ry team composed of general clinicians, urologists, 
ophthalmologists, dermatologists, nurses, nutritio-
nists and physiotherapists evaluated the patients.
Men between the ages of 40 and 70 years 
old were submitted to a urological evaluation, which 
consisted of a clinical history, International Prostate 
Symptom Score (IPSS) (13), digital rectal examina-
tion (DRE), prostate-specific antigen (PSA), urinaly-
sis, and abdominal ultrasonography. The prostate size 
was measured by abdominal ultrasonography despite 
the limitations of this method. The digital rectal exa-
mination was performed in every patient over the age 
of 45 and/or over the age of 40 for those with a his-
tory of prostate cancer in their family, or whose race 
was African-American.
The inclusion criteria were men between 40 
and 70 years old, without previous history of prosta-
te and/or bladder cancer. The exclusion criteria were 
any type of bladder or prostate surgery, men who 
used testosterone in the last six months, or those who 
were using 5 alpha-reductase inhibitors.
All patients received an orientation (which 
was sent by email or mail postal service) two weeks 
before the check-up. Blood was drawn before begin-
ning the examination. With regards to PSA testing, 
men were instructed to avoid sexual activity 72h be-
fore the exam. In cases where the PSA test was gre-
ater than 4.0ng/dL, the blood draw was repeated to 
confirm the result. The PSA dosage was carried out 
using an ultra-sensible PSA assay with a detection 
limit of 0.003ng/dL.
Statistical analysis was performed using SPSS 
software version 15.0 for Windows. Pearson’s Chi-
-square test was used for comparison between non-
-numerical variables, while t-test and ANOVA was 
used for comparison between numeric variables. A p 
value of 0.05 was considered the cut off for statistical 
significance.
RESULTS
Of the total number of 5315 patients eva-
luated in this urological examination program 
from January to December 2011, 300 were exclu-
ded due to any one of the exclusion criteria lis-
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ted above. Thus, a total of 5015 men with an average 
age of 49.0 +/- 4.0 years completed the study. Out 
of 5015 men, 3880 (77.3%) were white and only 90 
(1.7%) were black. The overall prevalence of diabetes 
mellitus in our population was 3.9% (197/5015). The-
se demographic data are presented in Table-1.
The average PSA was less than 2.5ng/mL for 
all age groups. Older men had higher values of PSA, 
prostate size and IPSS score.Table-2 presents the ave-
rages of PSA, IPSS and prostate size of the 5015 men.
Further analysis was performed in order to 
correlate different PSA cutoffs with aging, IPSS, and 
prostate size. The first cutoff was 2.5ng/mL. Out of 
5015 men included in this study, 4723 (94.17%) had 
PSA less than 2.5ng/mL, 192 (3.8%) had PSA betwe-
en 2.5 and 4.0ng/mL, and 100 (1.9%) had PSA greater 
than 4.0ng/mL. The prevalence of PSA > 2.5ng/mL 
was higher in older men. Higher PSA levels correla-
ted with higher IPSS and larger prostate size. These 
data are presented in Table-3.
A total of 192 men had PSA between 2.5 
and 4ng/mL. Among these men 130 were sub-
mitted to prostate biopsy. The predictive positi-
ve value of prostate biopsy was 25% (32/130). 
Table 1 - Demographic data of 5015 men.
40 - 49 years 50 - 59 years 60 - 70 years p
N 2813 (56%) 1726 (34.5%) 476 (9.5%) 0.001
Race
White 2700 (95.1%) 1650 (95.5%) 430 (90.3%) 0.01
Black 50 (1.7%) 30 (1.8%) 10 (2.2%) 0.02
Others 63 (2.2%) 46 (2.7%) 36 (7.5%) 0.04
Smoking 279 (9.9%) 189 (10.9%) 35 (7.3%) 0.03
Diabetes 54 (1.9%) 89 (5.1%) 54 (11.3%) 0.01
BMI (Kg/m2) 27.04 ± 4.9 27.6 ± 4.5 27.4 ± 5.3 0.59
BMI: Body Mass Index
Table 2 - Averages of total PSA, IPSS and Prostate size of the 5015 men.
40-49 years 50-59 years 60-70 years p
Men 2813 (56%) 1726 (34.5%) 476 (9.5%) 0.01
Total PSA (ng/dL) 0.9 ± 0.7 1.2 ± 0.5 1.7 ± 1.5 0.01
IPSS ≤ 7 2797 (99.4%) 1642 (95.1%) 381 (80%) 0.03
IPSS > 7 16 (0.6%) 84 (4.9%) 95 (20%) 0.03
Prostate Size (grams) 25.2 ± 7.3 30.9 ± 11.2 38 ± 18.8 0.03
Suspicious DRE 17/2813 63/1726 50/476 0.02
IPSS: International Prostate Symptom Score; DRE: Digital Rectal Examination
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The Gleason score was 6 in 24 men (75%), and 
7 in 8 men (25%). In the same way, 100 patients 
had PSA ≥ 4ng/mL. From these men, 80 were 
submitted to prostate biopsy. In this group, the 
predictive positive value of prostate biopsy was 
40% (32/100). The Gleason score was 6 in 19 men 
(60%), 7 in 10 men (31%) and 8 in 3 men (9%). 
Regarding the treatment option of each patient, 
we do not have the follow-up. These data are 
presented in Table-4.
The second cutoff point used for statistical 
analysis was 1.5ng/mL. Out of 5015 men, 3978 
(79.3%) had PSA less than 1.5ng/mL. As well as 
for 2.5ng/mL cutoff, the prevalence of PSA > 
1.5ng/mL also increased with age, and was quite 
similar in men between the ages of 50 and 59, 
and greater than 60 years of age (38.6% and 36% 
respectively). These data are presented in Table-5.
DISCUSSION
The primary objective of this study was to 
evaluate the PSA levels in a large population of 
young Brazilian men submitted to a health che-
ck-up program. The second objective was to cor-
relate the different PSA cutoff with age, prostate 
size, and urinary symptoms. The data was collec-
ted in Sao Paulo, Brazil, from one of the largest 
check up program ever performed in a private 
hospital. This study was obtained from a databa-
se of 5015 men between the ages of 40 and 70, 
with an average age of 49 years old. Most of the 
Table 3 - Prevalence of PSA less than 2.5, PSA between 2.5 and 4.0, and PSA greater than 4.0ng/dL in the different aging groups.
PSA< 2.5ng/dL PSA 2.5 to 4.0ng/dL PSA>4.0ng/dL p
Age
40-49 years 2763 (98.2%) 35 (1.2%) 15 (0.6%) 0.01
50-59 years 1575 (91.2%) 108 (6.2%) 43 (2.6%) 0.03
60-70 years 385 (80.8%) 49 (10.2%) 42 (9%) 0.04
IPSS
40-49 years 0.37 ± 0.1 0.6 ± 0.2 0.78 ± 0.4 0.01
50-59 years 1.01 ± 0.3 1.6 ± 0.5 2.4 ± 0.9 0.01
60-70 years 2.5 ± 0.7 2.4 ± 0.9 4.6 ± 1.9 0.01
Prostate Size
40-49 years 25 ± 2.3 27 ± 4 29 ± 7 0.01
50-59 years 28 ± 3 30.2 ± 5 35 ± 3 0.01
60-70 years 32.5 ± 2 38.5 ± 5 43.7 ± 7 0.01
Free PSA ng/dL
40-49 years 0.54 ± 0.2 0.69 ± 0.2 0.03
50-59 years 0.62 ± 0.15 0.77 ± 0.3 0.01
60-70 years 0.79 ± 0.4 0.83 ± 0.5 0.05
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Table 4 - The prevalence of PSA greater or less than 1.5ng/dL and its correlation with IPSS and prostate size.
40-49 years 50-59 years 60-70 years p
N 2813 1726 476
PSA < 1.5ng/dL 2612 (92.8) 1061 (62.4%) 305 (64%) 0.02
PSA > 1.5ng/dL 201 (7.2%) 665 (38.6%) 171 (36%) 0.02
Avg IPSS
PSA < 1.5ng/dL 0.33 ± 0.1 0.95 ± 0.4 2.5 ± 1.3 0.03
PSA > 1.5ng/dL 0.64 ± 0.2 1.6 ± 0.7 3.8 ± 1.7 0.03
Avg Prostate Size
PSA < 1.5ng/dL 23.3 ± 3 30.1 ± 5 30 ± 7 0.02
PSA > 1.5ng/dL 27 ± 8 33 ± 7 35.9 ± 9 0.01
Avg: Average; IPSS: International Prostate Symptom Score
Table 5 - The prevalence of PSA greater or less than 1.5ng/dL and its correlation with IPSS and prostate size.
PSA < 1.5ng/dL PSA > 1.5ng/dL p
Age
40-49 years 2612 (92.8%) 201 (7.2%) 0.02
50-59 years 1061 (62,4%) 665 (38.6%) 0.02
60-70 years 305 (64%) 171 (36%) 0.02
IPSS
40-49 years 0.33 ± 0.1 0.64 ± 0.2 0.03
50-59 years 0.95 ± 0.4 1.6 ± 0.7 0.03
60-70 years 2.5 ± 1.3 3.8 ± 1.7 0.03
Prostate Size (grams)
40-49 years 23.3 ± 3 27 ± 8 0.01
50-59 years 30.1 ± 5 33 ± 7 0.02
60-70 years 30 ± 7 35.9 ± 9 0.01
subjects were white, non-smokers, without co-
-morbidities such as diabetes, and have no uro-
logical complaints. The averages of total PSA in 
the three different aging groups were 0.9ng/mL 
for men between the ages of 40 and 50; 1.2ng/
mL for men between 50 and 60; and 1.7ng/mL 
for men greater than 60 years old. Out of 5015 
men, 4820 (96.11%) had an IPSS less or equal 
to 7. The prevalence of PSA greater than 2.5ng/
mL was 1.8% in men between the ages of 40 and 
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50; 8.8% between 50 and 60; and 11.1% after 60 
years of age. Only 20.6% had a PSA level greater 
than 1.5ng/mL. The predictive positive value of 
prostate biopsy in men with PSA between 2.5 to 
4ng/mL was 25% and all of them had Gleason 
score ≤ 7. In the same way, the predictive posi-
tive value of prostate biopsy in men with PSA ≥ 
4ng/mL was 40% and 91% of them had Gleason 
score ≤ 7.
The primary goal of prostate cancer scre-
ening in this specific population of younger men 
is the early detection of prostate cancer. Re-
garding prostate screening programs, men can 
potentially fall into 1 of 3 categories: 1) those 
whose cancer will result in death despite early 
diagnosis and treatment; 2) those who will have 
good outcomes in the absence of screening; and 
3) those for whom early diagnosis and treatment 
improve survival.
There is convincing evidence that with or 
without screening the number of men who survi-
ve prostate cancer after 10 to 14 years is, at best, 
very small (14, 15). In addition, the inevitabili-
ty of overdiagnosis and overtreatment of pros-
tate cancer as a result of screening means that 
many men will experience the adverse effects of 
diagnosis and treatment of a disease that would 
have remained asymptomatic throughout their 
lifetime. In accordance with the U.S. Preventive 
Services Task Force (USPSTF) statement of re-
commendations published in 2012, there is mo-
derate certainty that the benefits of PSA-based 
screening for prostate cancer do not outweigh its 
harmful effects (3).
False positive PSA test results are com-
mon and vary depending on the PSA cutoff and 
frequency of screening. After four PSA tests, men 
in the screening group of the PLCO trial had a 
12.9% cumulative risk for at least 1 false posi-
tive result, and a 5.5% risk for at least 1 biopsy 
due to a false positive result. A false positive re-
sult has a negative impact on patient’s quality of 
life (4, 14). The ProtecT study found that 32% of 
men submitted to a prostate biopsy experienced 
pain; fever; blood in the urine, semen, or stool; 
infection; transient urinary difficulties; or other 
issues that they considered a moderate or major 
problem (9).
In the present study, the majority of men 
was white and less than 50 years old. According 
to recent data, the recommendation of PSA scre-
ening in this specific population remains contro-
versial. It is well established that age, race, and 
family history of prostate cancer increase the 
risk of developing and dying of the disease. Bla-
ck men are approximately twice as likely to die 
of prostate cancer than other men, and the rea-
son for this disparity is unknown (16). Prelimi-
nary results from PIVOT (Prostate Cancer Inter-
vention Versus Observation Trial), in which 30% 
of enrollees were black, found no difference in 
outcomes due to treatment of prostate cancer in 
these men compared with other races (17). Des-
pite controversies, the 2013 American Urological 
Association Guidelines recognized that the PSA 
screening test might benefit certain subgroups 
of younger men with high risk of prostate can-
cer. However, this report suggests that patients 
should be informed about the potential harmful 
effects of these tests as well as the benefits of 
screening at an earlier age. Physicians should be 
aware that there are no comparative data and the 
best approach for this specific group is not well 
established (18).
The PSA-based screening in men 50 to 74 
years of age has been evaluated in 5 randomized, 
controlled trials with different cutoffs and scre-
ening intervals. The PLCO trial found a nonsta-
tistically significant increase in prostate cancer 
mortality in the annual screening group at 11.5 
and 13 years post diagnosis (4, 14). The ERSPC 
trial demonstrated a mortality ratio (RR) of 0.80 
(95% CI, 0.65 to 0.98) in screened men after a 
median follow up of 9 years, with similar findin-
gs at 11 years (RR 0.79, CI 0.68 to 0.91) (5, 15). 
In the present study 2080 (41.4%) men were older 
than 50 years of age, 4723 (94.17%) had PSA less 
than 2.5ng/dL, and 3978 (79.3%) had PSA less 
than 1.5ng/dL.
In a prevalence study and clinical signifi-
cance of prostate cancer among 12682 men with 
normal DRE and low PSA levels Pepe et al. have 
shown that 27.4% of men with PSA between 2.5 
and 4ng/mL had prostate cancer and some of 
them were clinically significant (19). Another re-
cent study published by Faria et al. evaluated the 
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detection rates, clinical and pathological findings 
in Brazilian men with serum PSA levels <4ng/
mL. In this study the predictive positive value 
of prostate biopsy in men with PSA between 2.5 
and 3.9ng/mL was 31.1%. All patients had cli-
nical stage I and 96.8% had Gleason score ≤ 7. 
After radical prostatectomy, 82.4% had patholo-
gical stage T2 and 17.6% had pathological stage 
T3 (20). In our study we have found similar re-
sults regarding prostate biopsy predictive positi-
ve value. For patients with PSA between 2.5 and 
3.9ng/mL, 25% had prostate cancer and all of 
them had Gleason score ≤ 7. On the other hand, 
the predictive positive value of prostate biopsy 
in patients with PSA ≥ 4ng/mL was 40% and 9% 
had Gleason score > 7.
The conventional PSA cutoff of 4.0ng/dL 
detects most cases of prostate cancer; however, 
some cases will be missed. Using a lower cuto-
ff point detects more cases of cancer but at the 
cost of labeling more men as potentially having 
the disease. When the PSA cutoff decreases to 
2.5ng/dL more than double the number of men 
aged 40 to 69, with abnormal results, show a fal-
se positive result. This cutoff level also increases 
the likelihood of detection of indolent tumors 
with no clinical importance. Conversely, increa-
sing the PSA cutoff to a level greater than 10ng/
dL would reduce a prostate cancer diagnosis in 
the number of men aged 50 to 69 with abnormal 
results from 1.2 million to roughly 352,000. It 
is important to note there is no PSA cutoff at 
which a man can be guaranteed to be free from 
prostate cancer (21, 22).
Despite the benefits of this large popu-
lation sample of Brazilian men who underwent 
this urological examination, the limitations of 
this study must be recognized. First, it was per-
formed with patients referred to a private hospi-
tal, who have a good health insurance and a bet-
ter medical care whether compared to the whole 
Brazilian population. Second, our database did 
not have patient family history information. 
Third, 60 cases with PSA between 2.5 and 2.9ng/
dL, and 20 cases with PSA > 4.0ng/dL were not 
submitted to prostate biopsies. This precludes 
accurate conclusions regarding prostate cancer 
incidence in this population.
The idea of prostate screening implies 
that most asymptomatic prostate cancers could 
become clinically important and lead to poor 
health outcomes, and that early treatment could 
effectively reduce prostate cancer specifically 
and thereby reduce mortality rates overall. Ho-
wever, long-term, population based cohort stu-
dies, and randomized treatment trials of conser-
vatively managed men with localized prostate 
cancer do not support this hypothesis (6).
Our database showed that the PSA level 
in Brazilian men submitted to a health check-up 
program was low. In this context, it should be 
emphasized that lower PSA levels do not exclude 
prostate cancer. According to some population-
-based studies, approximately 25% of men with 
PSA < 4.0ng/dL will have prostate cancer with 
Gleason score higher than 6.
The PSA level had a positive correlation 
with age, prostate size and prostate symptoms. 
Despite some of the limitations, we believe that 
this study provides substantial information 
about PSA screening tests performed in youn-
ger men from underdeveloped countries. To our 
knowledge this study represents the first urolo-
gical Brazilian-database report carried out with 
this large number of patients.
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